Reunion Neuroscience Inc. (NASDAQ: REUN / TSX: REUN), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today reported fiscal results for the fourth quarter and year ended March 31, 2023 and provided a corporate update. Corporate Updates On June 1, 2023, Reunion announced that it has agreed…